Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape. In this interview, conducted at the 2025 LUGPA Annual Meeting, Joshua J. Meeks, ...

Liu notes that current data—showing a response rate of just over 50%—indicate that the BCG-unresponsive CIS cohort is the most appropriate initial target population. In this video, Jen-Jane Liu, MD, ...

DSUI's 2025 report emphasizes advancements in urology through visionary leadership, innovation, and transformative technologies, including AI-powered diagnostics and interdisciplinary research. Dr.

212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy. According to Hansen, 212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy (RLT) being developed for patients with ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 mg/m2 docetaxel regimen. Despite a higher cumulative docetaxel dose, the 50 ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

A panelist discusses how the choice between microformulation abiraterone and off-label low-dose regimens is often dictated by cost and insurance coverage rather than purely clinical considerations.

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.

“We're now entering an era of new types of technologies to treat BPH in a minimally invasive fashion,” says Dean Elterman, MD. “We're now entering an era of new types of technologies to treat BPH in a ...

"For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR. "I think a ...

The Visby Medical test is the first at-home, prescription-free diagnostic for chlamydia, gonorrhea, and trichomoniasis. It provides results in approximately 30 minutes using a self-collected vaginal ...

Experts discuss the frequency of cystectomy use in patients with non–muscle-invasive bladder cancer (NMIBC) and how often patients are requesting bladder-sparing treatments. Stay current with the ...